Hi thanks for asking. Great question.At the January 2023...

Hi thanks for asking. Great question.

At the January 2023 roadshow, the CEO John McCutcheon said (from memory) that target sales revenue after the first 12 months post FDA Approval is US 10 million. Somewhere it’s in print too. That would be achieved by selling to the 45 clinical sites in the USA that had participated in the clinical trials. Of course, they are already familiar with the product and the implanting procedure. The unit sale per device would be US 35000 (from the presentation slides.) So that’s about 6 sales per site per annum to get to 10 million.

I think it’s a realistically achievable goal. As sites become more experienced with the implanting procedure, with attendant favourable patient outcomes, sales should double in the following 12 months. Meanwhile the EBR sales team will find it easier to expand to new clinics. According to EBR’s presentation slides, about 250 clinical sites account for half the cardiac resynchronisation procedures performed annually in the US…of the now estimated US 2.6 billion initially addressable market.

Part of the reason for last year’s capital raise was to fund a specialist sales force. Let’s hope this is a good omen!

DYOR and good luck.